Pemphigus Vulgaris - Pipeline Review, H1 2020
Pemphigus Vulgaris - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pemphigus Vulgaris – Pipeline Review, H1 2020, provides an overview of the Pemphigus Vulgaris (Immunology) pipeline landscape.
Pemphigus vulgaris is a rare autoimmune disease that causes painful blistering on the skin and the mucous membranes. Risk factors include race, gender and age. Symptoms of pemphigus vulgaris include painful blisters that start in the mouth, skin blisters that come and go; the blisters always occur near the surface of the skin and oozing, crusting, or peeling at the blister site.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pemphigus Vulgaris – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Pemphigus Vulgaris (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pemphigus Vulgaris (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Pemphigus Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 2, 1, 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Pemphigus Vulgaris (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pemphigus Vulgaris – Pipeline Review, H1 2020, provides an overview of the Pemphigus Vulgaris (Immunology) pipeline landscape.
Pemphigus vulgaris is a rare autoimmune disease that causes painful blistering on the skin and the mucous membranes. Risk factors include race, gender and age. Symptoms of pemphigus vulgaris include painful blisters that start in the mouth, skin blisters that come and go; the blisters always occur near the surface of the skin and oozing, crusting, or peeling at the blister site.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pemphigus Vulgaris – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Pemphigus Vulgaris (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pemphigus Vulgaris (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Pemphigus Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 2, 1, 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Pemphigus Vulgaris (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pemphigus Vulgaris (Immunology).
- The pipeline guide reviews pipeline therapeutics for Pemphigus Vulgaris (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pemphigus Vulgaris (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pemphigus Vulgaris (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pemphigus Vulgaris (Immunology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pemphigus Vulgaris (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pemphigus Vulgaris (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Pemphigus Vulgaris - Overview
Pemphigus Vulgaris - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pemphigus Vulgaris - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pemphigus Vulgaris - Companies Involved in Therapeutics Development
Alexion Pharmaceuticals Inc
Argenx SE
Biogen Inc
Cabaletta Bio Inc
Daewoong Pharmaceutical Co Ltd
Declion Pharmaceuticals Inc
HanAll Biopharma Co Ltd
iBio Inc
Novartis AG
Octagon Therapeutics Inc
Pharmapraxis
Principia Biopharma Inc
Topas Therapeutics GmbH
Pemphigus Vulgaris - Drug Profiles
batoclimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Pemphigus Vulgaris - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DPC-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWP-212525 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
efgartigimod alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target DSG1 and DSG3 for Mucocutaneous Pemphigus Vulgaris - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target DSG3 for Pemphigus Vulgaris - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ianalumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
orilanolimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OW-177 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rilzabrutinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biobetter - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPM-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pemphigus Vulgaris - Dormant Projects
Pemphigus Vulgaris - Discontinued Products
Pemphigus Vulgaris - Product Development Milestones
Featured News & Press Releases
May 06, 2020: Cabaletta Bio receives FDA Fast Track Designation for DSG3-CAART for the treatment of Mucosal Pemphigus Vulgaris
Jan 29, 2020: FDA grants DSG3-CAART orphan drug designation for the treatment of pemphigus vulgaris
Dec 18, 2019: Topas Therapeutics announces first patient enrolled in phase 1 trial with TPM203 in pemphigus vulgaris
Oct 14, 2019: Roche’s Rituxan outperforms MMF in pemphigus vulgaris study
Oct 01, 2019: Cabaletta Bio receives IND clearance from FDA to initiate first clinical trial of DSG3-CAART in patients with Mucosal Pemphigus Vulgaris
Jun 12, 2019: Phase III PEMPHIX study showed that Genentech's Rituxan (Rituximab) is superior to standard of care in achieving sustained remission in patients with Pemphigus Vulgaris
Mar 15, 2019: EC approves Roche’s MabThera for pemphigus vulgaris
Mar 02, 2019: Principia Biopharma announces positive data from phase 2 pemphigus vulgaris trial at 2019 American Academy of Dermatology Annual Meeting in Late-Breaking Presentation
Feb 22, 2019: Principia Biopharma announces the acceptance of data from phase 2 Pemphigus Vulgaris trial as a late-breaking presentation at 2019 American Academy of Dermatology meeting
Jan 31, 2019: CHMP recommended extension of indication for Mabthera
Dec 12, 2018: Cell therapy industry pioneer, Gwendolyn Binder, Ph.D., to join Cabaletta Bio leadership team
Jul 24, 2018: argenx announces publication of full data from Phase 1 healthy volunteer study of efgartigimod in Journal of Clinical Investigation
Jun 20, 2018: argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris
Jun 14, 2018: argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation
Jun 07, 2018: FDA Approves Genentech's Rituxan (rituximab) For Pemphigus Vulgaris
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Pemphigus Vulgaris - Overview
Pemphigus Vulgaris - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pemphigus Vulgaris - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pemphigus Vulgaris - Companies Involved in Therapeutics Development
Alexion Pharmaceuticals Inc
Argenx SE
Biogen Inc
Cabaletta Bio Inc
Daewoong Pharmaceutical Co Ltd
Declion Pharmaceuticals Inc
HanAll Biopharma Co Ltd
iBio Inc
Novartis AG
Octagon Therapeutics Inc
Pharmapraxis
Principia Biopharma Inc
Topas Therapeutics GmbH
Pemphigus Vulgaris - Drug Profiles
batoclimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Pemphigus Vulgaris - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DPC-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWP-212525 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
efgartigimod alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target DSG1 and DSG3 for Mucocutaneous Pemphigus Vulgaris - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target DSG3 for Pemphigus Vulgaris - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ianalumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
orilanolimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OW-177 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rilzabrutinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biobetter - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPM-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pemphigus Vulgaris - Dormant Projects
Pemphigus Vulgaris - Discontinued Products
Pemphigus Vulgaris - Product Development Milestones
Featured News & Press Releases
May 06, 2020: Cabaletta Bio receives FDA Fast Track Designation for DSG3-CAART for the treatment of Mucosal Pemphigus Vulgaris
Jan 29, 2020: FDA grants DSG3-CAART orphan drug designation for the treatment of pemphigus vulgaris
Dec 18, 2019: Topas Therapeutics announces first patient enrolled in phase 1 trial with TPM203 in pemphigus vulgaris
Oct 14, 2019: Roche’s Rituxan outperforms MMF in pemphigus vulgaris study
Oct 01, 2019: Cabaletta Bio receives IND clearance from FDA to initiate first clinical trial of DSG3-CAART in patients with Mucosal Pemphigus Vulgaris
Jun 12, 2019: Phase III PEMPHIX study showed that Genentech's Rituxan (Rituximab) is superior to standard of care in achieving sustained remission in patients with Pemphigus Vulgaris
Mar 15, 2019: EC approves Roche’s MabThera for pemphigus vulgaris
Mar 02, 2019: Principia Biopharma announces positive data from phase 2 pemphigus vulgaris trial at 2019 American Academy of Dermatology Annual Meeting in Late-Breaking Presentation
Feb 22, 2019: Principia Biopharma announces the acceptance of data from phase 2 Pemphigus Vulgaris trial as a late-breaking presentation at 2019 American Academy of Dermatology meeting
Jan 31, 2019: CHMP recommended extension of indication for Mabthera
Dec 12, 2018: Cell therapy industry pioneer, Gwendolyn Binder, Ph.D., to join Cabaletta Bio leadership team
Jul 24, 2018: argenx announces publication of full data from Phase 1 healthy volunteer study of efgartigimod in Journal of Clinical Investigation
Jun 20, 2018: argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris
Jun 14, 2018: argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation
Jun 07, 2018: FDA Approves Genentech's Rituxan (rituximab) For Pemphigus Vulgaris
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Pemphigus Vulgaris, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pemphigus Vulgaris - Pipeline by Alexion Pharmaceuticals Inc, H1 2020
Pemphigus Vulgaris - Pipeline by Argenx SE, H1 2020
Pemphigus Vulgaris - Pipeline by Biogen Inc, H1 2020
Pemphigus Vulgaris - Pipeline by Cabaletta Bio Inc, H1 2020
Pemphigus Vulgaris - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2020
Pemphigus Vulgaris - Pipeline by Declion Pharmaceuticals Inc, H1 2020
Pemphigus Vulgaris - Pipeline by HanAll Biopharma Co Ltd, H1 2020
Pemphigus Vulgaris - Pipeline by iBio Inc, H1 2020
Pemphigus Vulgaris - Pipeline by Novartis AG, H1 2020
Pemphigus Vulgaris - Pipeline by Octagon Therapeutics Inc, H1 2020
Pemphigus Vulgaris - Pipeline by Pharmapraxis, H1 2020
Pemphigus Vulgaris - Pipeline by Principia Biopharma Inc, H1 2020
Pemphigus Vulgaris - Pipeline by Topas Therapeutics GmbH, H1 2020
Pemphigus Vulgaris - Dormant Projects, H1 2020
Pemphigus Vulgaris - Discontinued Products, H1 2020
Number of Products under Development for Pemphigus Vulgaris, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pemphigus Vulgaris - Pipeline by Alexion Pharmaceuticals Inc, H1 2020
Pemphigus Vulgaris - Pipeline by Argenx SE, H1 2020
Pemphigus Vulgaris - Pipeline by Biogen Inc, H1 2020
Pemphigus Vulgaris - Pipeline by Cabaletta Bio Inc, H1 2020
Pemphigus Vulgaris - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2020
Pemphigus Vulgaris - Pipeline by Declion Pharmaceuticals Inc, H1 2020
Pemphigus Vulgaris - Pipeline by HanAll Biopharma Co Ltd, H1 2020
Pemphigus Vulgaris - Pipeline by iBio Inc, H1 2020
Pemphigus Vulgaris - Pipeline by Novartis AG, H1 2020
Pemphigus Vulgaris - Pipeline by Octagon Therapeutics Inc, H1 2020
Pemphigus Vulgaris - Pipeline by Pharmapraxis, H1 2020
Pemphigus Vulgaris - Pipeline by Principia Biopharma Inc, H1 2020
Pemphigus Vulgaris - Pipeline by Topas Therapeutics GmbH, H1 2020
Pemphigus Vulgaris - Dormant Projects, H1 2020
Pemphigus Vulgaris - Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development for Pemphigus Vulgaris, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Alexion Pharmaceuticals Inc
Argenx SE
Biogen Inc
Cabaletta Bio Inc
Daewoong Pharmaceutical Co Ltd
Declion Pharmaceuticals Inc
HanAll Biopharma Co Ltd
iBio Inc
Novartis AG
Octagon Therapeutics Inc
Pharmapraxis
Principia Biopharma Inc
Topas Therapeutics GmbH
Number of Products under Development for Pemphigus Vulgaris, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Alexion Pharmaceuticals Inc
Argenx SE
Biogen Inc
Cabaletta Bio Inc
Daewoong Pharmaceutical Co Ltd
Declion Pharmaceuticals Inc
HanAll Biopharma Co Ltd
iBio Inc
Novartis AG
Octagon Therapeutics Inc
Pharmapraxis
Principia Biopharma Inc
Topas Therapeutics GmbH
